Navigation Links
UH Case Medical Center publishes study on novel treatment for skin lymphoma
Date:1/17/2012

CLEVELAND: Promising findings on a novel combination treatment approach for a chronic type of skin lymphoma are being published today (embargoed for 4 pm) in JAMA's Archives of Dermatology by clinical researchers from Seidman Cancer Center at University Hospitals (UH) Case Medical Center and Case Western Reserve University School of Medicine.

The article outlines findings from a first-of-its-kind study showing that O6-benzylguanine is successful in treating cutaneous T-Cell lymphoma by enhancing the efficacy of topical chemotherapy (carmustine).

"Current therapy for cutaneous T-Cell lymphoma is suboptimal and this new study shows that adding O6-benzylguanine to carmustine is more effective and less toxic to the skin, allowing for more optimal treatments," says Kevin Cooper, MD, Chairman of the Department of Dermatology at UH Case Medical Center and Case Western Reserve University School of Medicine. "This treatment essentially weakens the cancer cells to make the lymphoma more vulnerable to topical chemotherapy and has a lot of potential in alleviating patients' disease burden in this chronic and progressive disease."

Cutaneous T-cell lymphoma is a form of lymphoma which affects the skin and typically relapses and becomes increasingly challenging to treat. The new drug combination offers a potential new option for patients using skin-directed treatments, before the need to undergo systemic chemotherapy.

Clinical researchers at UH Case Medical Center and Case Western Reserve University have been investigating O6-benzylguanine over the past decade and were participants in the original research into its mechanism of action as a cancer treatment potentiator. This study, funded by National Cancer Institute grants to Case Western Reserve University in conjunction with Keryx Pharmaceuticals Inc., is the first to explore the drug's efficacy to intensify treatment for skin lymphoma.

When used alone, carmustine attaches to the DNA in the patient's cancer cells during the replication process, causing the cancer cells to die. Problems sometimes occur when an enzyme clips off the treatment from the DNA, allowing the cancer cells to replicate. O6-benzylguanine inhibits the enzyme from clipping off the carmustine from the DNA, so the drug can complete its mission and kill the cancer cells.

"By adding O6-benzylguanine, we can effectively lower the dosage of the topical treatment, carmustine, and render it less toxic on healthy cells but more effective at killing cancer cells," says Dr. Cooper. "This combination treatment has had excellent initial clinical results and we are following it up with additional ongoing studies."


'/>"/>
Contact: Alicia Reale
alicia.reale@uhhospitals.org
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Surgical robots to provide open-source platform for medical robotics research
2. CCNYs Robert Alfano wins first biomedical optics award
3. CareFirst BCBS and ACP offer new tool to advance development of patient-centered medical homes
4. Use of acupuncture in the US military highlighted in special issue of Medical Acupuncture
5. Lingua franca critical for electronic medical records and health information exchange
6. Self-affirmation may break down resistance to medical screening
7. Society of Interventional Radiology Foundation receives support from Siemens Medical
8. FDA Seeks to Get More Women Into Trials of Medical Devices
9. Experts Urge Limits on Medical Research on Chimpanzees
10. UW Medical Center granted magnet status for excellence in nursing care
11. Nations largest federation of biological and biomedical organizations welcomes 2 new members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... ... ... and Overseer at The House of Yahweh, has written a new article this week meant ... to stop cancer. Yisrayl says there are too many suffering and dying from the disease ... will pay close attention and take action. The Pastor says that the root cause of ...
(Date:5/6/2016)... ... May 06, 2016 , ... This Mother’s Day kicks ... everywhere. The 17th annual National Women’s Health Week takes place May 8-May ... Health are combining forces to empower women to make their health a top priority. ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... at CareFirst Blue Cross BlueShield and Former Principal Deputy Administrator at Centers for ... an Anthem Company; Steve Ondra, MD, Chief Medical Officer at Health Care Service ...
(Date:5/5/2016)... WA (PRWEB) , ... May 05, 2016 , ... ... ranking for overall select performance in the industry’s gold standard KLAS ... The Epic Consulting report assessed organizations that specialize in consulting services for ...
(Date:5/5/2016)... ... 05, 2016 , ... The U.S. Food and Drug Administration ... to submit their products through an arduous federal approval process. The rules, which ... the market since February 15, 2007. That would essentially ban 99 percent of ...
Breaking Medicine News(10 mins):
(Date:5/6/2016)... , May 6, 2016  Hill-Rom Holdings, Inc. (NYSE: ... of Directors declared a fiscal year 2016 third quarter ... percent increase over the amount paid a year ago. ... record as of the close of business on June 10, ...    Hill-Rom is a leading global medical technology ...
(Date:5/5/2016)... , May 5, 2016 Endo International plc ... appointment of Douglas S. Ingram , former president of ... Todd B. Sisitsky , managing partner of TPG Capital, ... "Endo recently embarked ... complement, enhance and expand the Board,s capabilities. Doug and Todd ...
(Date:5/5/2016)... Research and Markets has announced the addition ... EU Markets"  report to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... the current Positron Emission Tomography (PET) scanner and cyclotron install ... includes France , Germany ... and the United Kingdom . Along ...
Breaking Medicine Technology: